Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

William E Plautz, BS, Mitchell Dyer, MD MSc, Margaret V. Ragni, MD MPH, Shannon Haldeman, Wyeth E Alexander, BS, Jason Sperry, Francis Guyette, Brian Zuckerbraun, Marian A. Rollins-Raval, MD MHP, Jay S Raval, MD, Matthew D Neal, MD

Blood (2019) 134 (Supplement_1): 444.

https://doi.org/10.1182/blood-2019-124531

Published: 2019

Journal Articles

Transfusion-Dependent Anemia and Coagulopathy in a Porcine Model of Pediatric Extracorporeal Membrane Oxygenation (ECMO)

Christopher Robert Reed, MD, Desiree Bonadonna, MPS, Jeffrey R Everitt, DVM, Victoria Robinson, BA, James Otto, PhD, Gowthami Arepally, MD, Elisabeth T Tracy, MD

Blood (2019) 134 (Supplement_1): 1164.

https://doi.org/10.1182/blood-2019-124524

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects

Nausheen Baig, Ahmed Kouta, Fakiha Siddiqui, Ambar Farooqui, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Cassie Bacher, Sharan Krishnappan, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 3665.

https://doi.org/10.1182/blood-2019-126075

Published: 2019

Journal Articles

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Fakiha Siddiqui, Siddharth Mehrotra, Vishnu Venkitasubramony, Rithik Raina, Lorenzo Storino Ramacciotti, Jack Bontekoe, BS, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Jawed Fareed, PhD

Blood (2018) 132 (Supplement 1): 2520.

https://doi.org/10.1182/blood-2018-99-116993

Published: 2018

Journal Articles

Bovine Heparin Compared to Porcine Heparin to Demonstrate Bioequivalence

Marco Khiella, Walter Jeske, PhD, Jeanine Walenga, PhD, Omer Iqbal, MD, Rajan Laddu, Fakiha Siddiqui, Mamdouh Bakhos, MD

Blood (2018) 132 (Supplement 1): 1253.

https://doi.org/10.1182/blood-2018-99-118809

Published: 2018

Journal Articles

Poor Platelet Function on Sonoclot Signature Is Associated with High Incidence of Bleeding in Severe Immune Thrombocytopenia

Kundan Mishra, MD MBBS, MNAMS, Aditya Jandial, MD MBBS, Rajeev Sandal, MD, Pradakshna Porchezhian, MBBS, Samson Charan, MBBS, Lad Deepesh Pravin Kumar, Gaurav Prakash, MD DM, Alka Khadwal, MD, R K Dhiman, MD DM, Neelam Varma, MD, Pankaj Malhotra, MD

Blood (2018) 132 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2018-99-117086

Published: 2018

Journal Articles

Bleeding Risk Assessment By Sonoclot in Severe Immune Thrombocytopenia

Kundan Mishra, MD MBBS, MNAMS, Pankaj Malhotra, MD, Aditya Jandial, MBBS, MD, Lad Deepesh Pravin Kumar, Neelam Varma, MBBS, MD, R K Dhiman, MD DM, Uday Yanamandra, MBBS, Alka Khadwal, MD, Gaurav Prakash, Jasmina Ahluwalia, MD, Subhash Varma, MBBS, MD

Blood (2017) 130 (Supplement 1): 2320.

https://doi.org/10.1182/blood.V130.Suppl_1.2320.2320

Published: 2017

Journal Articles

Evaluation of the Procoagulant Properties of Freshly Prepared Platelet Microparticles As Compared to Fresh and Stored Platelets

Hannah L McRae, Grace Conley, Majed A. Refaai, MD

Blood (2016) 128 (22): 2635.

https://doi.org/10.1182/blood.V128.22.2635.2635

Published: 2016

Journal Articles

RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit

Ruwan Gunaratne, MA, James Frederiksen, MD, Nabil K. Thalji, BS, Michelle D Ho, Gowthami M Arepally, MD, Rodney M. Camire, PhD, Bruce A. Sullenger, PhD

Blood (2016) 128 (22): 3823.

https://doi.org/10.1182/blood.V128.22.3823.3823

Published: 2016

Journal Articles

Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications

Zafar Siddiqui, Parul Aggarwal, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Mary Lewis, Schuharazad Abro, MD, Kazuhisa Tsuruta, PhD, Jawed Fareed, PhD

Blood (2016) 128 (22): 4974.

https://doi.org/10.1182/blood.V128.22.4974.4974

Published: 2016

Journal Articles

Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols

Andreas Hanslik, Erwin Kitzmüller, Ulrich S. Tran, Katharina Thom, Hratsch Karapetian, Nicole Prutsch, Jasmin Voitl, Ina Michel-Behnke, Fiona Newall, Christoph Male

Blood (2015) 126 (18): 2091–2097.

https://doi.org/10.1182/blood-2015-06-651661

Published: 2015

Journal Articles

A Novel Role of Protein Disulfide Isomerase in Calpain Regulated Hypoxia Induced Prothrombotic Phenotype

Tarun Tyagi, MSc, Amit Prabhakar, MSc, Shantanu Sengupta, PhD, Mohammad Z Ashraf, PhD

Blood (2014) 124 (21): 1530.

https://doi.org/10.1182/blood.V124.21.1530.1530

Published: 2014

Journal Articles

Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation

Jawed Fareed, Ph.D., Debra Hoppensteadt, Ph.D., Omer Iqbal, MD, Schuharazad Abro, MD, Martin Emanuele, PhD

Blood (2013) 122 (21): 4770.

https://doi.org/10.1182/blood.V122.21.4770.4770

Published: 2013

Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Crowther Mark, MD, Mathur Vandana, MD, Kitt Michael, MD, Lu Genmin, PhD, Pamela B. Conley, Ph.D., Hollenbach Stanley, JD, Janice Castillo, Athiwat Hutchaleelaha, Ph.D., Mark Karbarz, Ph.D., Joyce P. Lin, Lee Barron, PhD, Sandra Russell, R.N, Gallia G. Levy, MD, PhD, Stuart Connolly, M.D., John T. Curnutte, MD, PhD

Blood (2013) 122 (21): 3636.

https://doi.org/10.1182/blood.V122.21.3636.3636

Published: 2013

Journal Articles

Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs

Jawed Fareed, Ph.D., Michael J Moorman, III, Walter Jeske, Ph.D., Debra Hoppensteadt, Ph.D.

Blood (2013) 122 (21): 4804.

https://doi.org/10.1182/blood.V122.21.4804.4804

Published: 2013

Journal Articles

Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents

Jawed Fareed, PhD, Debra Hoppensteadt, Omer Iqbal, MD, Josephine Cunanan, MD, Vinod Bansal, MD, Schuharazad Abro, Rakesh Wahi, MD

Blood (2012) 120 (21): 3411.

https://doi.org/10.1182/blood.V120.21.3411.3411

Published: 2012

Journal Articles

Revisiting the Role of the Stat Laboratory: Is It Safe to Perform Activated Clotting Time Determinations (ACTs) Out of the Operating Room

Michael Plietz, Aaron Leifer, MD, Vilma Padilla, Carole Pineda, Khrishan Naraine, Mark Greenberg, MD, Amy S Fox, MD, MS

Blood (2012) 120 (21): 4256.

https://doi.org/10.1182/blood.V120.21.4256.4256

Published: 2012

Journal Articles

Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran,

Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Josephine Cunanan, MD, Omer Iqbal, MD, Bruce E Lewis, MD, Evi Kalodiki, PhD, Stephen Kahn, Jawed Fareed, PhD

Blood (2011) 118 (21): 3363.

https://doi.org/10.1182/blood.V118.21.3363.3363

Published: 2011

Journal Articles

Reversal of Heparin by Novel Synthetic Antagonist PMX-60056 Exhibits a Linear Dose-Response Relationship

R. Eric McAllister, MD, DPhil

Blood (2010) 116 (21): 3329.

https://doi.org/10.1182/blood.V116.21.3329.3329

Published: 2010

NARROW

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

Transfusion-Dependent Anemia and Coagulopathy in a Porcine Model of Pediatric Extracorporeal Membrane Oxygenation (ECMO)

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Bovine Heparin Compared to Porcine Heparin to Demonstrate Bioequivalence

Poor Platelet Function on Sonoclot Signature Is Associated with High Incidence of Bleeding in Severe Immune Thrombocytopenia

Bleeding Risk Assessment By Sonoclot in Severe Immune Thrombocytopenia

Evaluation of the Procoagulant Properties of Freshly Prepared Platelet Microparticles As Compared to Fresh and Stored Platelets

RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit

Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications

Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols

A Novel Role of Protein Disulfide Isomerase in Calpain Regulated Hypoxia Induced Prothrombotic Phenotype

Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs

Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents

Revisiting the Role of the Stat Laboratory: Is It Safe to Perform Activated Clotting Time Determinations (ACTs) Out of the Operating Room

Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran,

Reversal of Heparin by Novel Synthetic Antagonist PMX-60056 Exhibits a Linear Dose-Response Relationship

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only